BR112012020556A2 - uso de sequência líder pten-long para transporte transmembrana de moléculas. - Google Patents
uso de sequência líder pten-long para transporte transmembrana de moléculas.Info
- Publication number
- BR112012020556A2 BR112012020556A2 BR112012020556A BR112012020556A BR112012020556A2 BR 112012020556 A2 BR112012020556 A2 BR 112012020556A2 BR 112012020556 A BR112012020556 A BR 112012020556A BR 112012020556 A BR112012020556 A BR 112012020556A BR 112012020556 A2 BR112012020556 A2 BR 112012020556A2
- Authority
- BR
- Brazil
- Prior art keywords
- molecules
- pten
- charge
- leader sequence
- transmembrane transport
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
uso de sequência líder pten-long para transporte transmembrana de moléculas. uma composição para a entrega de moléculas de carga através das membranas biológicas é fornecida compreendendo um peptídeo (i) compreendendo os resíduos de aminoácidos consecutivos com a sequência descrita em seq id no 1 para o transporte de uma molécula de carga através de uma membrana biológica e a moléculka de carga (ii), em que a molécula de carga não é um péptido compreendendo os resíduos de aminoácidos possuindo a sequência apresentada na seq id no 4. métodos de transporte de moléculas de carga através das membranas biológicas também são fornecidos. métodos de tratamento de um tumor, câncer, um distúrbio metabólico, e um dist´purbio cardiovascular são também fornecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33837710P | 2010-02-17 | 2010-02-17 | |
PCT/US2011/025312 WO2011103339A1 (en) | 2010-02-17 | 2011-02-17 | Use of pten-long leader sequence for transmembrane delivery of molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012020556A2 true BR112012020556A2 (pt) | 2017-01-10 |
BR112012020556A8 BR112012020556A8 (pt) | 2018-01-02 |
Family
ID=44483307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012020556A BR112012020556A8 (pt) | 2010-02-17 | 2011-02-17 | uso de sequência-líder pten-longa para liberação transmembrana de moléculas |
Country Status (9)
Country | Link |
---|---|
US (1) | US9074011B2 (pt) |
EP (1) | EP2536420A4 (pt) |
JP (1) | JP6009360B2 (pt) |
CN (1) | CN102844043B (pt) |
AU (1) | AU2011218037B2 (pt) |
BR (1) | BR112012020556A8 (pt) |
CA (4) | CA3017701C (pt) |
MX (1) | MX2012009565A (pt) |
WO (1) | WO2011103339A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2400973B1 (en) | 2009-02-17 | 2016-11-30 | The Trustees of Columbia University in the City of New York | Identification of extracellular form of pten that can be used to treat tumors |
CA2790203C (en) | 2010-02-19 | 2019-05-14 | Norman Latov | Inhibitor of macrophage scavenger receptor 1 (msr1) for the treatment of autoimmune demyelinating diseases |
CN108601850A (zh) * | 2015-10-19 | 2018-09-28 | 马萨诸塞大学 | 抗癌和抗炎症治疗及其方法 |
CA3032412A1 (en) * | 2016-07-29 | 2018-02-01 | Ohio State Innovation Foundation | Expression of pten-long with ocolytic viruses |
CN109022462B (zh) | 2017-06-08 | 2021-12-21 | 中山大学附属第一医院 | 一种PTEN基因的上游开放阅读框31aa-uORF核苷酸及其编码的多肽的应用 |
CN108504671A (zh) * | 2018-03-28 | 2018-09-07 | 宁波市医疗中心李惠利医院 | 一种PTEN-Long蛋白纯化制备方法 |
CN108484780A (zh) * | 2018-04-16 | 2018-09-04 | 河南大学 | 一种融合蛋白PTEN-L-p53及其应用 |
CN109224075B (zh) * | 2018-08-07 | 2021-11-16 | 浙江大学 | Pten抑制剂在制备治疗1型糖尿病药物中的应用 |
MX2021011815A (es) * | 2019-04-12 | 2021-10-22 | Therapten Biosciences Inc | Composiciones y metodos para fabricar fusiones de homologo de fosfatasa y tensina (pten). |
CN112877309B (zh) * | 2021-02-19 | 2022-05-17 | 北京大学 | 一种N端延长型PTEN亚型PTENζ蛋白及其编码基因和应用 |
CN113666998B (zh) * | 2021-08-10 | 2023-03-21 | 北京大学 | 一种具有调控神经系统发育功能的PTEN亚型蛋白PTENδ及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6482795B1 (en) | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
EP2400973B1 (en) | 2009-02-17 | 2016-11-30 | The Trustees of Columbia University in the City of New York | Identification of extracellular form of pten that can be used to treat tumors |
-
2011
- 2011-02-17 CA CA3017701A patent/CA3017701C/en not_active Expired - Fee Related
- 2011-02-17 WO PCT/US2011/025312 patent/WO2011103339A1/en active Application Filing
- 2011-02-17 AU AU2011218037A patent/AU2011218037B2/en not_active Ceased
- 2011-02-17 CA CA3017717A patent/CA3017717A1/en not_active Abandoned
- 2011-02-17 BR BR112012020556A patent/BR112012020556A8/pt not_active Application Discontinuation
- 2011-02-17 CA CA3017689A patent/CA3017689A1/en not_active Abandoned
- 2011-02-17 MX MX2012009565A patent/MX2012009565A/es active IP Right Grant
- 2011-02-17 JP JP2012554034A patent/JP6009360B2/ja not_active Expired - Fee Related
- 2011-02-17 US US13/579,025 patent/US9074011B2/en not_active Expired - Fee Related
- 2011-02-17 CN CN201180018210.8A patent/CN102844043B/zh not_active Expired - Fee Related
- 2011-02-17 EP EP11745260.7A patent/EP2536420A4/en not_active Withdrawn
- 2011-02-17 CA CA2790046A patent/CA2790046C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA3017701A1 (en) | 2011-08-25 |
EP2536420A4 (en) | 2016-02-24 |
CA2790046A1 (en) | 2011-08-25 |
CA3017717A1 (en) | 2011-08-25 |
CA2790046C (en) | 2018-10-30 |
AU2011218037B2 (en) | 2016-10-13 |
BR112012020556A8 (pt) | 2018-01-02 |
JP2013522168A (ja) | 2013-06-13 |
CA3017701C (en) | 2020-12-15 |
MX2012009565A (es) | 2014-02-27 |
WO2011103339A1 (en) | 2011-08-25 |
US20130171235A1 (en) | 2013-07-04 |
AU2011218037A1 (en) | 2012-10-04 |
CN102844043A (zh) | 2012-12-26 |
CA3017689A1 (en) | 2011-08-25 |
US9074011B2 (en) | 2015-07-07 |
JP6009360B2 (ja) | 2016-10-19 |
EP2536420A1 (en) | 2012-12-26 |
CN102844043B (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012020556A2 (pt) | uso de sequência líder pten-long para transporte transmembrana de moléculas. | |
Klaassen et al. | Xenobiotic, bile acid, and cholesterol transporters: function and regulation | |
ES2541217T3 (es) | Diferenciación de células madre mesenquimales | |
AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
AR080669A1 (es) | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina | |
AR074399A1 (es) | Moleculas biespecificas de union a egfr/igfir | |
CL2012003077A1 (es) | Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes. | |
CL2015003199A1 (es) | Peptidos terapeuticos | |
BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
BR112013010855A2 (pt) | luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso | |
CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
WO2008106507A3 (en) | Mdm2/mdmx inhibitor peptide | |
CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
BR112013006088A2 (pt) | Construto de entrega isolado, e, composição farmacêuticapolinucleotídeo que encodifica um construtor de entrega, vetor de expressão, e célula hospedeira isolada" | |
CL2019003427A1 (es) | Nuevos péptidos (seq id n°180), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
BR112012010661A2 (pt) | método para tratar insuficiência cardíaca com peptídeos semelhantes à estressecopina | |
CL2015001708A1 (es) | Polipétido que comprende el factor de crecimiento tipo insulina 1 (igf-1), donde el aminoácido glicina en posición 42 es suprimido o mutado; polinucléotido; composición farmacéutica que lo comprende; y uso para tratar un trastorno muscular, enefermedad pulmonar obstructiva o enfermedad crónica de riñón. | |
CL2008003357A1 (es) | Procedimiento para obtener una solucion de albumina humana con alta capacidad de union de moleculas que comprende una diafiltracion, estabilizacion con nacl y aminoacidos sin adicion de acidos grasos, pasteurizacion y una segunda diafiltracion. | |
BR112014019166A2 (pt) | promotores para expressão aumentada de proteína em meningococos | |
ES2542227T3 (es) | Tratamiento de complicaciones vasculares de diabetes | |
CL2009001284A1 (es) | Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos | |
BR112012030084A2 (pt) | peptídeos que se ligam a receptores do fator de crescimento semelhante à insulina tipo 1 | |
De Feo et al. | miR-214-3p is commonly downregulated by EWS-FLI1 and by CD99 and its restoration limits Ewing sarcoma aggressiveness | |
BR112021017853A2 (pt) | Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |